IL-37与过敏性疾病的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.04.005

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (4): 461-464.DOI: 10.3760/cma.j.issn.1007-1245.2023.04.005

IL-37与过敏性疾病的研究进展

高雯雯¹ 郅莉莉² 吴福玲³ 马立吉⁴

¹滨州医学院第一临床医学院，滨州　256600；²山东省千佛山医院变态反应科，济南　250000；³滨州医学院附属医院儿科，滨州　256600；⁴淄博市中心医院儿科，淄博　255000

收稿日期:2022-10-17 出版日期:2023-03-15 发布日期:2023-03-05
通讯作者: 马立吉，Email：malj125@126.com

Research progress of IL-37 and allergic diseases

Gao Wenwen¹, Zhi Lili², Wu Fuling³, Ma Liji⁴

¹First Clinical Medical College, Binzhou Medical University, Binzhou 256600, China; ²Department of Allergy, Shandong Qianfo Mountain Hospital, Jinan 250000, China; ³Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256600, China; ⁴Department of Pediatrics, Zibo Central Hospital, Zibo 255000, China

Received:2022-10-17 Online:2023-03-15 Published:2023-03-05
Contact: Ma Liji, Email: malj125@126.com

摘要/Abstract

摘要：

过敏性疾病是机体免疫系统对外来变应原产生的超敏反应性疾病，目前糖皮质激素作为治疗过敏性疾病的一线用药，其临床应用与治疗效果具有一定的局限性及不良反应。白细胞介素-37（interleukin-37，IL-37）作为天然的先天性和适应性免疫抑制剂，具有双重抗炎功能，可同时抑制炎症因子和激活抗炎因子的表达。研究表明，IL-37可通过多种作用机制及通路来维持过敏性疾病中免疫系统的动态平衡。因此，本文将基于分析IL-37的本身特性，对其在儿童常见的过敏性疾病中的作用机制作一综述，旨在为进一步研究和临床诊疗提供依据。

关键词:

白细胞介素-37, 过敏性哮喘, 变应性鼻炎, 特应性皮炎

Abstract:

Allergic diseases are diseases with hypersensitive reactions of the body's immune system to foreign allergens. Glucocorticoids are currently used as the first-line drugs in the treatment of allergic diseases, but their clinical application and therapeutic effect have certain limitations and by-effects. As a natural innate and adaptive immunosuppressive agent, interleukin-37 (IL-37) has dual anti-inflammatory functions. It can inhibit the expression of inflammatory factors and activate anti-inflammatory factors at the same time. Studies have shown that IL-37 can maintain the homeostasis of the immune system in patients with allergic diseases through a variety of mechanisms and pathways. This article reviews the mechanism of IL-37 in children's common allergic diseases based on the analysis of its own characteristics, so as to provide a basis for further research and clinical diagnosis and treatment.

Key words:

Interleukin-37, Allergic asthma, Allergic rhinitis, Atopic dermatitis

高雯雯郅莉莉吴福玲马立吉.

IL-37与过敏性疾病的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 461-464.

Gao Wenwen, Zhi Lili, Wu Fuling, Ma Liji.

Research progress of IL-37 and allergic diseases [J]. International Medicine and Health Guidance News, 2023, 29(4): 461-464.

参考文献

[1] Busfield SJ, Comrack CA, Yu G, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2[J]. Genomics, 2000,66(2):213-216. DOI: 10.1006/geno.2000.6184.
[2] Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family[J]. Eur Cytokine Netw, 2011, 22(3):127-147. DOI: 10.1684/ecn.2011.0288.
[3] Lv J, Yu Q, Lv J, et al. Airway epithelial TSLP production of TLR2 drives type 2 immunity in allergic airway inflammation[J]. Eur J Immunol, 2018,48(11):1838-1850. DOI: 10.1002/eji.201847663.
[4] Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37[J]. Immunol Rev, 2018,281(1):179-190. DOI: 10.1111/imr.12605.
[5] Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis[J]. Immunological reviews, 2018, 281(1): 138-153. DOI: 10.1111/imr.12616.
[6] Jia Y, Anwaar S, Li L, et al. A new target for the treatment of inflammatory bowel disease: Interleukin-37[J]. Int Immunopharmacol, 2020, 83: 106391. DOI: 10.1016/j.intimp.2020.106391.
[7] Huang Z, Xie L, Li H, et al. Insight into interleukin-37: the potential therapeutic target in allergic diseases[J]. Cytokine Growth Factor Rev, 2019, 49: 32-41. DOI: 10.1016/j.cytogfr.2019.10.003.
[8] Jartti T, Palomares O, Waris M, et al. Distinct regulation of tonsillar immune response in virus infection[J]. Allergy, 2014, 69(5): 658-667. DOI: 10.1111/all.12396.
[9] Bulau AM, Nold MF, Li S, et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses[J]. Proc Nat Acad Sci U S A, 2014, 111(7): 2650-2655. DOI: 10.1073/pnas.1324140111.
[10] Jiang M, Wang Y, Zhang H, et al. IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway[J]. Thoracic cancer, 2018, 9(5): 621-629. DOI: 10.1111/1759-7714.12628.
[11] Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8[J]. Proc Natl Acad Sci U S A, 2015,112(8):2497-2502. DOI: 10.1073/pnas.1424626112.
[12] Tsutsumi N, Kimura T, Arita K, et al. The structural basis for receptor recognition of human interleukin-18[J]. Nat Commun, 2014, 5: 5340. DOI: 10.1038/ncomms6340.
[13] Eisenmesser EZ, Gottschlich A, Redzic JS, et al. Interleukin-37 monomer is the active form for reducing innate immunity[J]. Proc Natl Acad Sci U S A, 2019,116(12):5514-5522. DOI: 10.1073/pnas.1819672116.
[14] Martin P, Goldstein JD, Mermoud L, et al. IL-1 family antagonists in mouse and human skin inflammation[J]. Front Immunol, 2021,12:652846. DOI: 10.3389/fimmu. 2021.652846.
[15] Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity[J]. Proc Natl Acad Sci U S A, 2002 ,99(21):13723-13728. DOI: 10.1073/pnas.212519099.
[16] Molgora M, Supino D, Mantovani A, et al. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8[J]. Immunol Rev, 2018,281(1):233-247. DOI: 10.1111/imr.12609.
[17] Vilia MG, Tocchetti M, Fonte E, et al. Characterization of a long isoform of IL-1R8 (TIR8/SIGIRR)[J]. Eur Cytokine Netw, 2017,28(2):63-69. DOI: 10.1684/ecn.2017.0395.
[18] Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase iia multiple basket study[J]. J Clin Oncol, 2018,36(6):536-542. DOI: 10.1200/JCO.2017.75.3780.
[19] Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity[J]. Nat Immunol,2010,11(11):1014-1022. DOI: 10.1038/ni.1944.
[20] Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis[J]. Int J Mol Sci, 2021,22(8):4130. DOI: 10.3390/ijms22084130.
[21] Hou T, Tsang MS, Kan LL, et al. IL-37 targets TSLP-primed basophils to alleviate atopic dermatitis[J]. Int J Mol Sci, 2021,22(14):7393. DOI: 10.3390/ijms22147393.
[22] Hou T, Sun X, Zhu J, et al. IL-37 ameliorating allergic inflammation in atopic dermatitis through regulating microbiota and AMPK-mTOR signaling pathway-modulated autophagy mechanism[J]. Front Immunol, 2020 ,11:752. DOI: 10.3389/fimmu.2020. 00752.
[23] Lv J, Xiong Y, Li W, et al. IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma[J]. Allergy, 2018,73(8):1642-1652. DOI: 10.1111/all.13395.
[24] Meng P, Chen ZG, Zhang TT, et al. IL-37 alleviates house dust mite-induced chronic allergic asthma by targeting TSLP through the NF-κB and ERK1/2 signaling pathways[J]. Immunol Cell Biol, 2019,97(4):403-415. DOI: 10.1111/imcb.12223.
[25] Huang N, Liu K, Liu J, et al. Interleukin-37 alleviates airway inflammation and remodeling in asthma via inhibiting the activation of NF-κB and STAT3 signalings[J]. Int Immunopharmacol, 2018,55:198-204. DOI: 10.1016/j.intimp.2017.12.010.
[26] Lunding L, Schröder A, Wegmann M. Allergic airway inflammation: unravelling the relationship between IL-37, IL-18Rα and Tir8/SIGIRR[J]. Expert Rev Respir Med, 2015,9(6):739-750. DOI: 10.1586/17476348.2015. 1109452.
[27] 高胜男.白介素37在支气管哮喘中的作用及其机制研究[D]. 北京:北京协和医学院,2021.
[28] 陈广道,吴子谕,刘运可,等.广州地区哮喘及变应性鼻炎和湿疹儿童血清特异性过敏原IgE的对比分析[J].国际医药卫生导报,2020,26(14):2104-2107.DOI:10.3760/cma.j.issn.1007-1245.2020.14.031.
[29] Wang L, Zhan M, Wang J, et al. Upregulated Expression of Toll-Like Receptor 7 in Peripheral Blood Basophils of Patients With Allergic Rhinitis[J]. Am J Rhinol Allergy, 2021, 35(6): 746-760. DOI: 10.1177/1945892421993034
[30] Zhong Q, Zhan M, Wang L, et al. Upregulation of the expression of Toll-like receptor 9 in basophils in patients with allergic rhinitis: an enhanced expression by allergens[J]. Scand J Immunol, 2021, 93(3): e13003. DOI: 10.1111/sji.13003
[31] Liu W, Deng L, Chen Y, et al. Anti-inflammatory effect of IL-37b in children with allergic rhinitis[J]. Mediators Inflamm, 2014, 2014: 746846. DOI: 10.1155/2014/746846
[32] Shen Y, Ke X, Yun L, et al. Decreased expression of interleukin37 and its antiinflammatory effect in allergic rhinitis[J]. Mol Med Rep, 2018, 17(1): 1333-1339. DOI: 10.3892/mmr.2017.7988

IL-37与过敏性疾病的研究进展

Research progress of IL-37 and allergic diseases

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	王晓华李念胜王晨霞王淑婷李程远. 孟鲁司特钠联合糠酸莫米松对变应性鼻炎患者的疗效 [J]. 国际医药卫生导报, 2023, 29(5): 652-655.
[2]	于云青. 针刺蝶腭神经节联合氯雷他定治疗变应性鼻炎的效果[J]. 国际医药卫生导报, 2022, 28(22): 3208-3211.